UTMB develops a universal vaccine platform that’s cheaper and shelf stable
Researchers at The University of Texas Medical Branch at Galveston have developed a less expensive way to produce vaccines that cuts the cost of vaccine production and storage by 80 percent without decreasing safety or effectiveness. The findings are currently available in EBioMedicine.
Vaccines are the most effective way to prevent and eradicate infectious diseases. Currently, many vaccines have to be manufactured in cell culture or eggs, which is expensive and carries the risk of contaminations. In addition, most vaccines must be kept refrigerated during the transportation from manufacturers to health care clinics. In tropical and subtropical regions, such cold storage requirements could contribute to more than 80 percent of the vaccine cost.
“The ability to eliminate cell culture or eggs and cold storage will change the process of vaccine development,” said UTMB’s Pei-Yong Shi, professor in the department of biochemistry and molecular biology. “Importantly, this vaccine technology could potentially serve as a universal platform for development of live-attenuated vaccines for many viral pathogens.”
To achieve these goals, the UTMB team engineered a live-attenuated Zika vaccine in the DNA form. Once the DNA is delivered into our body, it launches the vaccine in our cells, leading to antibody production and other protective immunity. With this production method, there is no need to manufacture the vaccine in cell culture or eggs at factories. Because DNA molecules are shelf stable, the vaccine will not expire at warm temperatures and could be stockpiled at room temperature for years.
Using UTMB’s Zika vaccine as a model, the research group showed that the DNA platform worked very efficiently in mice. After a single low dose, the DNA vaccine protected mice from Zika virus infection, mother-to-fetus transmission during pregnancy and male reproductive tract infection and damage.
“This is the first study to demonstrate that, after a single low dose, a DNA vaccine could induce saturated protective immunity,” Shi said. “We will continue testing this promising Zika vaccine platform and then apply the platform to other viruses.”
Learn more: UTMB develops a universal vaccine platform that’s cheaper and shelf stable
The Latest on: Vaccine production
[google_news title=”” keyword=”vaccine production” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Vaccine production
- Borno laments failure to produce vaccineson April 26, 2024 at 7:01 pm
Borno State has lamented the sharp contrast between Nigeria’s status as Africa’s largest economy and the country’s inability to produce vaccines for the treatment of common ailments.The state ...
- Avian Flu Threat Still Low and Vaccine Measures Are Readyon April 26, 2024 at 12:56 pm
One person in the United States has been infected after exposure to a cow with avian flu, but no human-to-human transmission has occurred.
- GSK pulls Pfizer and BioNTech into yet another COVID-19 vaccine patent lawsuiton April 26, 2024 at 7:04 am
Shortly after winning a stay on a COVID-19 vaccine patent lawsuit brought by Moderna, Pfizer and its German partner BioNTech are being dragged into another round of mRNA litigation by GSK. | GSK filed ...
- Study confirms effectiveness of bivalent COVID-19 vaccineon April 25, 2024 at 1:54 pm
A major bivalent COVID-19 vaccine induces production of neutralizing antibodies against the coronavirus that circulated at the start of the pandemic as well as subvariants of omicron, albeit less ...
- Demand for the cholera vaccine is soaring – this company might have a solutionon April 25, 2024 at 9:02 am
In the global race to provide enough vaccines to tackle the ever-growing threat posed by cholera, one company is leading the field.
- Applied DNA Awarded Contract by HDT Bio For Rapid Vaccine Development Programon April 25, 2024 at 6:24 am
Under the terms of the contract, Applied DNA will supply Linea™ DNA IVT templates to HDT Bio for use in conjunction with its LION™ formulated repRNA (self-replicating RNA) vaccination platform. The ...
- Vaccines are a glimmer of hope against malaria, but the battle has only just begunon April 25, 2024 at 6:10 am
By the time you reach the end of this article, three children will have died from malaria – a disease that casts a dark shadow over nearly half of the world’s population, claiming victims ...
- Malaria is still killing people in Kenya, but a vaccine and local drug production may helpon April 25, 2024 at 12:17 am
Malaria is still a significant public health challenge in Kenya, but an important pilot of the world’s first malaria vaccine may help.
- Massive amounts of H5N1 vaccine would be needed if there’s a bird flu pandemic. Can we make enough?on April 24, 2024 at 10:53 am
The first signs that H5N1 avian flu was starting to spread from person to person would trigger a race to produce massive amounts of vaccine.
via Bing News